Primary tumor receptor status for ER and/or PR (detected by IHC) and HER2 (evaluated by IHC or FISH) were positive in 21 (68%) and 3 (10%) out of 31 patients, respectively, while 8 (26%) out of 31 cases were triple-negative (ER-, PR- and HER2-negative). The gene discussed is ERBB2; the disease is neoplasm.